Quantum Leap | Biopharmaceutical R&D

CQDM’s funding program for Quantum Leap biopharmaceutical research helps Canadian SMEs and universities undertake innovative translational R&D projects in collaboration with large biopharmaceutical organizations. The chosen projects aim to develop cutting-edge technologies with a potentially significant impact on the R&D activities of CQDM biopharmaceutical members. Quantum Leap projects are undertaken in close collaboration and with expert support and funding from our pharmaceutical members.

Enabling technologies, pioneering platforms and/or innovative therapeutic methods developed should seek to improve, facilitate and/or considerably accelerate the discovery and development process for safer, more effective drugs. The technologies in question target all stages of drug development and cover a wide range of therapeutic indications.

Projects are expected to generate tangible deliverables to be used by CQDM’s pharmaceutical members, once the project has been completed. Funded research offers researchers a perfect opportunity to secure future collaborations with the industry worldwide.

• The enabling technologies, innovative platforms and/or innovative therapies derived from the Quantum Leap pharma-led funding program for drug discovery research are selected for their potential to significantly improve, facilitate and/or accelerate the drug discovery process and the development of safer and more effective drugs. The technologies of interest can be at any stage of the drug development process and involve a wide range of therapeutic indications.
   
• Projects are associated with specific deliverables and must be ready for use by CQDM pharmaceutical members upon completion. For scientists, the funded research opens new collaboration opportunities with world-class stakeholders in the industry.

Log in with Google

OR

Get Started to Apply